Alentis Therapeutics Appoints Luca Santarelli as Chairperson
Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Basel, Switzerland – 29 June 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board. “I’m pleased to welcome Luca as Chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company,” said Dr. Roberto…